A blister pack containing Neurontin anti-epileptic capsules, produced by Pfizer Inc., sits on a pharmacy counter in this arranged photograph in London, U.K., on Thursday, Dec. 29, 2016. The rapid pace of innovation among drugmakers may continue to be overshadowed by broader investment themes, such as the switch away from defensive stocks into more cyclical industries, during 2017, according to Bloomberg Intelligence. Photographer: Chris Ratcliffe/Bloomberg via Getty ImagesChris Ratcliffe — Bloomberg via Getty Images
- Previous Rank186
- Revenues ($M)52824
- Revenue Percent Change8.1
- Profits ($M)7215
- Profits Percent Change3.7
- Assets ($M)171615
- Employees96500
Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases–including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.
Company Information
CEO | Ian C. Read |
Sector | Health Care |
Industry | Pharmaceuticals |
HQ Location | New York, NY |
Website | www.pfizer.com |
Years on Global 500 List | 23 |
Employees | 96,500 |
Key Financials (Last Fiscal Year)
Revenues ($M) | $52,824 |
Profits ($M) | $7,215 |
Assets ($M) | $171,615 |
Total Stockholder Equity ($M) | $59,544 |
Profit Ratios
Profit as % of Revenues | 13.7% |
Profits as % of Assets | 4.2% |
Profits as % of Stockholder Equity | 12.1% |